CPT code 0060U designates the Panorama® Twin Zygosity Proprietary Laboratory Analyses test, a noninvasive genomic targeted sequencing assay on chromosome 2 applied to circulating cell–free fetal DNA in maternal blood to determine monozygosity versus dizygosity in twin pregnancies. This PLA code identifies a single manufacturer-specific test and matters nationally because it informs clinical management of twin gestations, impacts downstream prenatal care decisions, and is subject to payer coverage policies that vary across major insurers.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the service, common payer coverage considerations, and the clinical context in which the test is used. The publication provides benchmarks on coding and administrative handling for a manufacturer-specific PLA, summaries of typical sites of service, and notes on documentation clinicians and laboratories supply for medical necessity determinations.

This analysis emphasizes operational and policy-relevant information for national stakeholders: clinicians ordering the test, laboratory billing teams, and payer policy analysts. It highlights where data is available and explicitly notes when input fields were not provided. The content does not offer clinical recommendations but summarizes how CPT code 0060U is positioned within prenatal genetic testing workflows and payer interactions.